On the public citation graph
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer
0 signed · 1082 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/eji.200324506openalex-snapshot
Differential response of murine CD4+CD25+ and CD4+CD25– T cells to dexamethasone‐induced cell death
inferredcites →https://doi.org/10.1002/eji.200635873openalex-snapshot
Glucocorticoid amplifies IL‐2‐dependent expansion of functional FoxP3+CD4+CD25+ T regulatory cells in vivo and enhances their capacity to suppress EAE
inferredcites →https://doi.org/10.1007/s11060-009-0057-4openalex-snapshot
The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline
inferredcites →https://doi.org/10.1016/j.celrep.2014.04.041openalex-snapshot
How Steroids Steer T Cells
inferredcites →https://doi.org/10.1016/j.jpainsymman.2015.06.010openalex-snapshot
Pilot Study of a Brief Behavioral Intervention for Dyspnea in Patients With Advanced Lung Cancer
inferredcites →https://doi.org/10.1016/s0140-6736(16)32517-xopenalex-snapshot
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
inferredcites →https://doi.org/10.1016/s1470-2045(16)30498-3openalex-snapshot
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
inferredcites →https://doi.org/10.1038/nature19330openalex-snapshot
Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
inferredcites →https://doi.org/10.1056/nejmoa1500596openalex-snapshot
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
inferredcites →https://doi.org/10.1056/nejmoa1507643openalex-snapshot
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1056/nejmoa1606774openalex-snapshot
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1056/nejmra1703481openalex-snapshot
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
inferredcites →https://doi.org/10.1073/pnas.160099797openalex-snapshot
Inhibition of IL-2-induced Jak-STAT signaling by glucocorticoids
inferredcites →https://doi.org/10.1089/jpm.2011.0260openalex-snapshot
Dyspnea in Palliative Care: Expanding the Role of Corticosteroids
inferredcites →https://doi.org/10.1093/jnci/djn250openalex-snapshot
A Systematic Review and Meta-Analysis of the Pharmacological Treatment of Cancer-Related Fatigue
inferredcites →https://doi.org/10.1200/jco.2007.15.5796openalex-snapshot
Interventions for Alleviating Cancer-Related Dyspnea: A Systematic Review
inferredcites →https://doi.org/10.1200/jco.2012.44.4661openalex-snapshot
Reduction of Cancer-Related Fatigue With Dexamethasone: A Double-Blind, Randomized, Placebo-Controlled Trial in Patients With Advanced Cancer
inferredcites →https://doi.org/10.1200/jco.2013.54.3926openalex-snapshot
Efficacy of Methylprednisolone on Pain, Fatigue, and Appetite Loss in Patients With Advanced Cancer Using Opioids: A Randomized, Placebo-Controlled, Double-Blind Trial
inferredcites →https://doi.org/10.1200/jco.2015.60.8448openalex-snapshot
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
inferredcites →https://doi.org/10.1200/jco.2017.35.15_suppl.9012openalex-snapshot
Safety of retreatment with immunotherapy after immune-related toxicity in patients with lung cancers treated with anti-PD(L)-1 therapy.
inferredcites →https://doi.org/10.1200/jco.2017.35.15_suppl.9523openalex-snapshot
Management of gastrointestinal (GI) toxicity associated with nivolumab (NIVO) plus ipilimumab (IPI) or IPI alone in phase II and III trials in advanced melanoma (MEL).
inferredcites →https://doi.org/10.1200/jco.2017.73.2289openalex-snapshot
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials
inferredcites →https://doi.org/10.1200/jco.2018.36.18_suppl.lba9000openalex-snapshot
IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4593225openalex-extracted
First-Line Treatment for Patients with Advanced Squamous Non-Small Cell Lung Cancer: PD-(L)1 Inhibitors Plus Solvent-Based or Albumin-Bound Paclitaxel
inferred← citeshttps://doi.org/10.1001/jama.2020.5934openalex-snapshot
Reevaluation of the Frequent Use of PD-1 Checkpoint Inhibitors for Treatment of Glioblastoma
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2023.22915openalex-snapshot
Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non−Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2025.29225openalex-snapshot
Concomitant Comedications and Survival With First-Line Pembrolizumab in Advanced Non–Small-Cell Lung Cancer
inferred← citeshttps://doi.org/10.1001/jamaoncol.2019.2785openalex-snapshot
Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer
inferred← citeshttps://doi.org/10.1001/jamaoncol.2019.5570openalex-snapshot
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo
inferred← citeshttps://doi.org/10.1001/jamaoncol.2020.0409openalex-snapshot
Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non–Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1001/jamaoncol.2021.0729openalex-snapshot
Immune-Related Adverse Events and Efficacy—The More It Hurts, the Better It Works?
inferred← citeshttps://doi.org/10.1001/jamaoncol.2021.0732openalex-snapshot
Immune-Related Adverse Events and Efficacy—The More It Hurts, the Better It Works?—Reply
inferred← citeshttps://doi.org/10.1001/jamaoto.2019.0034openalex-snapshot
Association of Posttreatment Lymphopenia and Elevated Neutrophil-to-Lymphocyte Ratio With Poor Clinical Outcomes in Patients With Human Papillomavirus–Negative Oropharyngeal Cancers
inferred← citeshttps://doi.org/10.1002/14651858.cd014588openalex-snapshot
Immunotherapy for intracranial metastatic melanoma
inferred← citeshttps://doi.org/10.1002/1878-0261.13083openalex-snapshot
Prolonged estrogen deprivation triggers a broad immunosuppressive phenotype in breast cancer cells
inferred← citeshttps://doi.org/10.1002/9781394278886openalex-snapshot
Artificial Intelligence in Neuroscience
inferred← citeshttps://doi.org/10.1002/acr.25561openalex-snapshot
Survival in Immune Checkpoint Inhibitor–Treated Patients With Rheumatoid Arthritis and Non–Small Cell Lung Cancer: An Observational Cohort Study
inferred← citeshttps://doi.org/10.1002/acr2.11181openalex-snapshot
Higher Checkpoint Inhibitor Arthritis Disease Activity may be Associated With Cancer Progression: Results From an Observational Registry
inferred← citeshttps://doi.org/10.1002/adtp.201900215openalex-snapshot
Clinical Translation of Nanomedicine and Biomaterials for Cancer Immunotherapy: Progress and Perspectives
inferred← citeshttps://doi.org/10.1002/advs.202514261openalex-snapshot
Antiemesis Corticosteroids Potentiate Checkpoint Blockade Efficacy by Normalizing the Immune Microenvironment in Metastatic Murine Breast Cancer
inferred← citeshttps://doi.org/10.1002/art.41068openalex-snapshot
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study
inferred← citeshttps://doi.org/10.1002/art.41587openalex-snapshot
Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications
inferred← citeshttps://doi.org/10.1002/cac2.12512openalex-snapshot
Association of previously irradiated stable brain metastases with outcomes of atezolizumab‐treated non‐small cell lung cancer: A pooled analysis of individual patient data from three randomized trials
inferred← citeshttps://doi.org/10.1002/cam4.2397openalex-snapshot
Colitis after checkpoint blockade: A retrospective cohort study of melanoma patients requiring admission for symptom control
inferred← citeshttps://doi.org/10.1002/cam4.2807openalex-snapshot
Predictive factors for progression‐free survival in non‐small cell lung cancer patients receiving nivolumab based on performance status
inferred← citeshttps://doi.org/10.1002/cam4.3021openalex-snapshot
Toxicity and efficacy of Gamma Knife radiosurgery for brain metastases in melanoma patients treated with immunotherapy or targeted therapy—A retrospective cohort study
inferred← citeshttps://doi.org/10.1002/cam4.3675openalex-snapshot
Survival benefit from immunocheckpoint inhibitors in stage IV non‐small cell lung cancer patients with brain metastases: A National Cancer Database propensity‐matched analysis
inferred← citeshttps://doi.org/10.1002/cam4.3818openalex-snapshot
Recognizing encephalopathy in immune checkpoint inhibitor therapy: A single‐center experience
inferred← citeshttps://doi.org/10.1002/cam4.70254openalex-snapshot
Do corticosteroids affect immunotherapy efficacy in malignancy? – A systematic review
inferred← citeshttps://doi.org/10.1002/cam4.7142openalex-snapshot
Inconsistency in steroid use as antiemetics in clinical trial protocols involving immune checkpoint inhibitors combined with chemotherapy
inferred← citeshttps://doi.org/10.1002/ccr3.2027openalex-snapshot
Nivolumab and immune‐mediated colitis
inferred← citeshttps://doi.org/10.1002/ccr3.3973openalex-snapshot
Dissociated response related to corticosteroids in lung cancer treated by immunotherapy: A case report
inferred← citeshttps://doi.org/10.1002/cncr.32714openalex-snapshot
Current multidisciplinary management of brain metastases
inferred← citeshttps://doi.org/10.1002/cncr.34742openalex-snapshot
The impact of immunosuppressive agents on immune checkpoint inhibitor efficacy in patients with advanced melanoma: A real‐world, multicenter, retrospective study
inferred← citeshttps://doi.org/10.1002/cncr.35781openalex-snapshot
BRAF in non–small cell lung cancer: From molecular mechanisms to clinical practice
inferred← citeshttps://doi.org/10.1002/cpt.70424openalex-snapshot
Early and High‐Dose Glucocorticoid Use and Survival in Advanced NSCLC Receiving Immune Checkpoint Inhibitors: A Multicenter Target Trial Emulation
inferred← citeshttps://doi.org/10.1002/cti2.1050openalex-snapshot
Clinical chimeric antigen receptor‐T cell therapy: a new and promising treatment modality for glioblastoma
inferred← citeshttps://doi.org/10.1002/eji.70033openalex-snapshot
The Mitigating Effect of Combined Glucocorticoids with Immune Checkpoint Inhibitors on Lymphocyte Activation Gene‐3 and Programmed Death‐1 Expression
inferred← citeshttps://doi.org/10.1002/hep.32215openalex-snapshot
Effect of corticosteroid dosing on outcomes in high‐grade immune checkpoint inhibitor hepatitis
inferred← citeshttps://doi.org/10.1002/ijc.33503openalex-snapshot
Evolving landscape and academic attitudes toward the controversies of global immuno‐oncology trials
inferred← citeshttps://doi.org/10.1002/ijc.34628openalex-snapshot
Safety and efficacy of immune checkpoint blockade in patients with advanced nonsmall cell lung cancer and brain metastasis
inferred← citeshttps://doi.org/10.1002/ijc.34940openalex-snapshot
Tissue‐resident memory T cells in immunotherapy and immune‐related adverse events by immune checkpoint inhibitor
inferred← citeshttps://doi.org/10.1002/ijc.35261openalex-snapshot
Tislelizumab combined with nab‐paclitaxel and cisplatin as the more effective chemoimmunotherapy strategy in the neoadjuvant treatment of locally advanced thoracic esophageal squamous cell carcinoma: A prospective, two‐cohort, phase 2 trial
inferred← citeshttps://doi.org/10.1002/ijc.70009openalex-snapshot
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population
inferred← citeshttps://doi.org/10.1002/ijc.70069openalex-snapshot
Randomized, double‐blind phase III trial of a dexamethasone‐free regimen for managing highly emetogenic chemotherapy‐induced nausea and vomiting
inferred← citeshttps://doi.org/10.1002/iju5.12175openalex-snapshot
Successful pembrolizumab treatment in a patient with metastatic urothelial carcinoma and underlying overlap syndrome involving systemic sclerosis and systemic lupus erythematosus
inferred← citeshttps://doi.org/10.1002/iju5.12193openalex-snapshot
Editorial Comment to Successful pembrolizumab treatment in a patient with metastatic urothelial carcinoma and underlying overlap syndrome involving systemic sclerosis and systemic lupus erythematosus
inferred← citeshttps://doi.org/10.1002/iju5.12426openalex-snapshot
Remitting seronegative symmetrical synovitis with pitting edema syndrome induced by pembrolizumab in patient with urothelial carcinoma
inferred← citeshttps://doi.org/10.1002/iju5.12560openalex-snapshot
Seronegative rheumatoid arthritis after combination therapy with ipilimumab and nivolumab for postoperative pancreatic and liver metastases from renal cell carcinoma
inferred← citeshttps://doi.org/10.1002/iju5.12574openalex-snapshot
Editorial Comment on Seronegative rheumatoid arthritis after combination therapy with Ipilimumab and Nivolumab for postoperative pancreatic and liver metastases from renal cell carcinoma
inferred← citeshttps://doi.org/10.1002/jgh3.12875openalex-snapshot
Pancreatic adverse events in patients treated with immune checkpoint inhibitors
inferred← citeshttps://doi.org/10.1002/jvc2.27openalex-snapshot
Skin manifestations associated with checkpoint inhibitors
inferred← citeshttps://doi.org/10.1002/mco2.784openalex-snapshot
Neuroscience in peripheral cancers: tumors hijacking nerves and neuroimmune crosstalk
inferred← citeshttps://doi.org/10.1002/onco.13680openalex-snapshot
Reconsidering Dexamethasone for Antiemesis when Combining Chemotherapy and Immunotherapy
inferred← citeshttps://doi.org/10.1002/path.70095openalex-snapshot
Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of ‘‐mabs’?
inferred← citeshttps://doi.org/10.1002/phar.2364openalex-snapshot
Optimizing Patient Outcomes with PD‐1/PD‐L1 Immune Checkpoint Inhibitors for the First‐Line Treatment of Advanced Non–Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1002/rcr2.730openalex-snapshot
Complete response in a patient with lung cancer suffering from three pembrolizumab‐induced immune‐related adverse events including retinal vasculitis
inferred← citeshttps://doi.org/10.1002/wnan.1575openalex-snapshot
Immunoengineering in glioblastoma imaging and therapy
inferred← citeshttps://doi.org/10.1002/wnan.1730openalex-snapshot
Remodeling tumor microenvironment with nanomedicines
inferred← citeshttps://doi.org/10.1007/16833_2022_119openalex-snapshot
Lung Immunotherapy in the Elderly with NSCLC – the Who, the What, and the When
inferred← citeshttps://doi.org/10.1007/978-1-4614-7147-9_38openalex-snapshot
Cutaneous Adverse Events of Systemic Melanoma Treatments
inferred← citeshttps://doi.org/10.1007/978-1-4614-7322-0_38-1openalex-snapshot
Cutaneous Adverse Events of Systemic Melanoma Treatments
inferred← citeshttps://doi.org/10.1007/978-3-030-05070-2_31openalex-snapshot
Radiotherapy for Distant Melanoma Metastases
inferred← citeshttps://doi.org/10.1007/978-3-030-43740-4_8openalex-snapshot
Integrating Systemic Therapy into the Management of Brain Metastases
inferred← citeshttps://doi.org/10.1007/978-3-030-47682-3_15openalex-snapshot
Development of Immunotherapeutic Strategies for Early Phase Clinical Trials
inferred← citeshttps://doi.org/10.1007/978-3-030-56824-5_13openalex-snapshot
Cancer Immunotherapy in Patients with Preexisting Rheumatic Diseases: Other Rheumatic Autoimmune Diseases
inferred← citeshttps://doi.org/10.1007/978-3-030-56824-5_4openalex-snapshot
Immune-Related Adverse Events with Immune Checkpoint Inhibitors: Arthritis
inferred← citeshttps://doi.org/10.1007/978-3-030-74028-3_7openalex-snapshot
Spectrum and Management of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors
inferred← citeshttps://doi.org/10.1007/978-3-030-80962-1_124-1openalex-snapshot
Autoimmunity and Cancer
inferred← citeshttps://doi.org/10.1007/978-3-030-80962-1_215-1openalex-snapshot
Immunotherapy and Cancer: The Pharmacists’ Perspective
inferred← citeshttps://doi.org/10.1007/978-3-030-80962-1_349-1openalex-snapshot
Pulmonary Side Effects of Immunotherapy
inferred← citeshttps://doi.org/10.1007/978-3-030-93702-7_12-1openalex-snapshot
Immune Checkpoint Inhibition
inferred← citeshttps://doi.org/10.1007/978-3-030-93702-7_12-2openalex-snapshot
Immune Checkpoint Inhibition
inferred← citeshttps://doi.org/10.1007/978-3-030-99918-6_25openalex-snapshot
Anti-neoplastic Immunomodulatory Treatments and the Pituitary
inferred← citeshttps://doi.org/10.1007/978-3-031-05002-2_18openalex-snapshot
Arthritis Associated with Immune Checkpoint Inhibitors
inferred← citeshttps://doi.org/10.1007/978-3-031-22483-6_69-1openalex-snapshot
Immunotherapy for Non-small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1007/978-3-031-29277-4_23openalex-snapshot
Cutaneous Adverse Events from Systemic Anticancer Treatments
inferred← citeshttps://doi.org/10.1007/978-3-031-39005-0_11openalex-snapshot
Case Study #2: Disialoganglioside GD2 as a Target for Radiopharmaceutical Therapy
inferred← citeshttps://doi.org/10.1007/978-3-031-67878-3_49openalex-snapshot
Novel Systemic Therapies for Solid Tumor Brain Metastases
inferred← citeshttps://doi.org/10.1007/978-3-031-83533-9_26openalex-snapshot
Immune Checkpoint Inhibitor Use in Patients with Pre-Existing Inflammatory Bowel Disease
inferred← citeshttps://doi.org/10.1007/978-3-032-00761-2_124openalex-snapshot
Autoimmunity and Cancer
inferred← citeshttps://doi.org/10.1007/978-3-032-00767-4_215openalex-snapshot
Immunotherapy and Cancer: The Pharmacists’ Perspective
inferred← citeshttps://doi.org/10.1007/978-3-032-00775-9_349openalex-snapshot
Pulmonary Side Effects of Immunotherapy
inferred← citeshttps://doi.org/10.1007/978-3-319-46029-1_31-1openalex-snapshot
Radiotherapy for Distant Metastases
inferred← citeshttps://doi.org/10.1007/s00092-022-5501-1openalex-snapshot
Immunbedingte Toxizitäten behandeln
inferred← citeshttps://doi.org/10.1007/s00108-021-01036-7openalex-snapshot
Abstracts zum 127. Kongress der Deutschen Gesellschaft für Innere Medizin e.V.
inferred← citeshttps://doi.org/10.1007/s00259-019-04615-xopenalex-snapshot
Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors
inferred← citeshttps://doi.org/10.1007/s00262-019-02416-7openalex-snapshot
Pembrolizumab for anaplastic thyroid cancer: a case study
inferred← citeshttps://doi.org/10.1007/s00262-019-02462-1openalex-snapshot
Comparable outcomes of nivolumab in patients with advanced NSCLC presenting with or without brain metastases: a retrospective cohort study
inferred← citeshttps://doi.org/10.1007/s00262-020-02555-2openalex-snapshot
The glucocorticoids prednisone and dexamethasone differentially modulate T cell function in response to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade
inferred← citeshttps://doi.org/10.1007/s00262-020-02760-zopenalex-snapshot
The effects of targeted immune-regulatory strategies on tumor-specific T-cell responses in vitro
inferred← citeshttps://doi.org/10.1007/s00262-020-02786-3openalex-snapshot
Antibiotics and steroids, the double enemies of anticancer immunotherapy: a review of the literature
inferred← citeshttps://doi.org/10.1007/s00262-021-02851-5openalex-snapshot
Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncology
inferred← citeshttps://doi.org/10.1007/s00262-021-02855-1openalex-snapshot
Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors
inferred← citeshttps://doi.org/10.1007/s00262-021-02875-xopenalex-snapshot
Normalization of electroretinogram and symptom resolution of melanoma-associated retinopathy with negative autoantibodies after treatment with programmed death-1 (PD-1) inhibitors for metastatic melanoma
inferred← citeshttps://doi.org/10.1007/s00262-021-02985-6openalex-snapshot
Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group
inferred← citeshttps://doi.org/10.1007/s00262-022-03224-2openalex-snapshot
Brain metastases and immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1007/s00262-022-03360-9openalex-snapshot
Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study
inferred← citeshttps://doi.org/10.1007/s00280-019-03861-yopenalex-snapshot
Clinical implications of an analysis of pharmacokinetics of crizotinib coadministered with dexamethasone in patients with non-small cell lung cancer
inferred← citeshttps://doi.org/10.1007/s00280-020-04205-xopenalex-snapshot
Impact of interstitial lung disease associated with immune checkpoint inhibitors on prognosis in patients with non-small-cell lung cancer
inferred← citeshttps://doi.org/10.1007/s00280-022-04416-4openalex-snapshot
Impact of previous corticosteroid exposure on outcomes of patients receiving immune checkpoint inhibitors for advanced non-small cell lung cancer: a retrospective observational study
inferred← citeshttps://doi.org/10.1007/s00280-022-04418-2openalex-snapshot
Anti-drug antibodies in the current management of cancer
inferred← citeshttps://doi.org/10.1007/s00393-020-00825-zopenalex-snapshot
Diagnostik und Management rheumatischer „immune-related adverse events“
inferred← citeshttps://doi.org/10.1007/s00408-026-00932-9openalex-snapshot
Unveiling BRAF Mutations in Non-small Cell Lung Cancer: State of the Art and Future Perspectives
inferred← citeshttps://doi.org/10.1007/s00432-020-03299-3openalex-snapshot
RETRACTED ARTICLE: Comprehensive characterization of tumor mutation burden in clear cell renal cell carcinoma based on the three independent cohorts
inferred← citeshttps://doi.org/10.1007/s00432-022-04425-zopenalex-snapshot
Association between skin immune-related adverse events (irAEs) and multisystem irAEs during PD-1/PD-L1 inhibitor monotherapy
inferred← citeshttps://doi.org/10.1007/s00432-023-04736-9openalex-snapshot
Effects of immunosuppressive treatment on patient outcomes after immune checkpoint inhibitor-related gastrointestinal toxicity
inferred← citeshttps://doi.org/10.1007/s00520-021-06359-7openalex-snapshot
Preexisting autoimmune disease is a risk factor for immune-related adverse events: a meta-analysis
inferred← citeshttps://doi.org/10.1007/s00520-025-09268-1openalex-snapshot
Effect of antiemetic corticosteroids on the development of immune-related adverse events caused by chemoimmunotherapy: a multicenter retrospective study
inferred← citeshttps://doi.org/10.1007/s10067-020-05420-wopenalex-snapshot
Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors—is it time for a paradigm shift?
inferred← citeshttps://doi.org/10.1007/s10147-021-01896-xopenalex-snapshot
Outcomes of patients with non-small cell lung cancer and poor performance status treated with immune checkpoint inhibitors in the real-world setting
inferred← citeshttps://doi.org/10.1007/s10147-023-02349-3openalex-snapshot
Systematic surveillance of immune-related adverse events in clinical practice and impact of subsequent steroid medication on survival outcomes
inferred← citeshttps://doi.org/10.1007/s10147-024-02622-zopenalex-snapshot
Clinical impact of concomitant BIO-three use in advanced or recurrent non-small cell lung cancer treated with immune-checkpoint inhibitor
inferred← citeshttps://doi.org/10.1007/s10157-023-02415-0openalex-snapshot
Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022
inferred← citeshttps://doi.org/10.1007/s10238-023-01230-xopenalex-snapshot
Systemic immunity markers are associated with clinical outcomes of atezolizumab treatment in patients with triple-negative advanced breast cancer: a retrospective multicenter observational study
inferred← citeshttps://doi.org/10.1007/s10405-019-00276-7openalex-snapshot
Immuntherapie des metastasierten nichtkleinzelligen Lungenkarzinoms
inferred← citeshttps://doi.org/10.1007/s10637-019-00843-yopenalex-snapshot
Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001)
inferred← citeshttps://doi.org/10.1007/s10637-023-01414-yopenalex-snapshot
A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for a cisplatin-containing regimen. - PATROL-I-
inferred← citeshttps://doi.org/10.1007/s10741-024-10406-wopenalex-snapshot
New insights gained from cellular landscape changes in myocarditis and inflammatory cardiomyopathy
inferred← citeshttps://doi.org/10.1007/s11033-023-08423-3openalex-snapshot
The PD-1 single‐nucleotide polymorphism rs11568821 and rs2227981 as a novel prognosis model in a triple-negative breast cancer patient
inferred← citeshttps://doi.org/10.1007/s11060-019-03121-2openalex-snapshot
Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD)
inferred← citeshttps://doi.org/10.1007/s11060-020-03439-2openalex-snapshot
Glucocorticoids and immune checkpoint inhibitors in glioblastoma
inferred← citeshttps://doi.org/10.1007/s11060-020-03450-7openalex-snapshot
T-Cell based therapies for overcoming neuroanatomical and immunosuppressive challenges within the glioma microenvironment
inferred← citeshttps://doi.org/10.1007/s11060-020-03583-9openalex-snapshot
Autoimmune disease-related primary CNS lymphoma: systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1007/s11060-025-05120-yopenalex-snapshot
Management outcomes for biopsy-proven radiation necrosis in patients with brain metastases in the era of immune-checkpoint blockade
inferred← citeshttps://doi.org/10.1007/s11154-025-09989-yopenalex-snapshot
Management of cushing’s syndrome in patients with adrenocortical cancer: state of the art and future perspectives
inferred← citeshttps://doi.org/10.1007/s11523-021-00825-2openalex-snapshot
Prognostic Impact of Early Treatment Interruption of Nivolumab Plus Ipilimumab Due to Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Multi-Institution Retrospective Study
inferred← citeshttps://doi.org/10.1007/s11523-024-01069-6openalex-snapshot
Survival Impact of Glucocorticoid Administration for Adverse Events During Immune Checkpoint Inhibitor Combination Therapy in Patients with Previously Untreated Advanced Renal Cell Carcinoma
inferred← citeshttps://doi.org/10.1007/s11523-024-01084-7openalex-snapshot
Risk Stratification According to Baseline and Early Change in Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Treated with Chemoimmunotherapy: A Multicenter Real-World Study
inferred← citeshttps://doi.org/10.1007/s11523-025-01190-0openalex-snapshot
Beyond Proton Pump Inhibitors: Evaluating Treatment Strategies for Immune-Mediated Gastroenteritis from Cancer Immunotherapy
inferred← citeshttps://doi.org/10.1007/s11560-019-00390-wopenalex-snapshot
Renale Toxizitäten von Checkpoint-Inhibitoren bei onkologischen Therapien
inferred← citeshttps://doi.org/10.1007/s11560-020-00424-8openalex-snapshot
Nebenwirkungen neuer onkologischer Immuntherapien
inferred← citeshttps://doi.org/10.1007/s11864-019-0619-4openalex-snapshot
Current State of Immunotherapy for Treatment of Glioblastoma
inferred← citeshttps://doi.org/10.1007/s11864-020-00771-7openalex-snapshot
Optimal Management of Corticosteroids in Patients with Intracranial Malignancies
inferred← citeshttps://doi.org/10.1007/s11864-022-00977-xopenalex-snapshot
Do Patients Benefit from a Trial of Corticosteroids at the End of Life?
inferred← citeshttps://doi.org/10.1007/s11864-023-01155-3openalex-snapshot
Systemic Therapy for Melanoma Brain and Leptomeningeal Metastases
inferred← citeshttps://doi.org/10.1007/s11894-020-0752-zopenalex-snapshot
Gastrointestinal and Hepatic Complications of Immunotherapy: Current Management and Future Perspectives
inferred← citeshttps://doi.org/10.1007/s11894-022-00852-7openalex-snapshot
Update on Immune Checkpoint Inhibitor Enterocolitis
inferred← citeshttps://doi.org/10.1007/s11910-020-01054-2openalex-snapshot
Neurological and Medical Complications in Brain Tumor Patients
inferred← citeshttps://doi.org/10.1007/s11910-021-01142-xopenalex-snapshot
Medical and Neurological Management of Brain Tumor Complications
inferred← citeshttps://doi.org/10.1007/s11912-026-01789-0openalex-snapshot
Immunological Drug–Drug Interactions in Immune Checkpoint Inhibitor Therapy: Mechanisms, Clinical Evidence, and Artificial Intelligence
inferred← citeshttps://doi.org/10.1007/s11926-024-01173-6openalex-snapshot
Immune Checkpoint Inhibitor Associated Rheumatoid Arthritis
inferred← citeshttps://doi.org/10.1007/s11936-023-01024-0openalex-snapshot
Immunotherapy-Associated Atherosclerosis: A Comprehensive Review of Recent Findings and Implications for Future Research
inferred← citeshttps://doi.org/10.1007/s12012-024-09918-6openalex-snapshot
Steroid-Refractory Myocarditis Induced by Immune Checkpoint Inhibitor Responded to Infliximab: Report of Two Cases and Literature Review
inferred← citeshttps://doi.org/10.1007/s12016-022-08930-4openalex-snapshot
Systemic Sclerosis Association with Malignancy
inferred← citeshttps://doi.org/10.1007/s12029-024-01095-7openalex-snapshot
Concomitant Medications Alter Clinical Outcomes in Patients with Advanced Digestive Tract Cancer Receiving PD-1 Checkpoint Inhibitors Combined with Antiangiogenetic Agents
inferred← citeshttps://doi.org/10.1007/s12032-020-01440-3openalex-snapshot
Impact of preexisting antinuclear antibodies on combined immunotherapy and chemotherapy in advanced non-small cell lung cancer patients
inferred← citeshttps://doi.org/10.1007/s12032-024-02591-3openalex-snapshot
Concomitant medication effects on patients with lung cancer taking immune checkpoint inhibitors a review
inferred← citeshttps://doi.org/10.1007/s12094-020-02397-5openalex-snapshot
Anti-PD-1/L1-associated immune-related adverse events as harbinger of favorable clinical outcome: systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1007/s12094-025-04133-3openalex-snapshot
Do glucocorticoids affect the efficacy of immune checkpoint inhibitors?
inferred← citeshttps://doi.org/10.1007/s12325-019-00909-6openalex-snapshot
Maximum Tolerated Dose and Pharmacokinetics of Paclitaxel Micellar in Patients with Recurrent Malignant Solid Tumours: A Dose-Escalation Study
inferred← citeshttps://doi.org/10.1007/s12328-025-02207-xopenalex-snapshot
Long-term survival after resolution of pulmonary metastasis in a patient with unresectable cervical esophageal carcinoma after nivolumab-induced immune-related adverse events
inferred← citeshttps://doi.org/10.1007/s12672-023-00758-4openalex-snapshot
A target map of clinical combination therapies in oncology: an analysis of clinicaltrials.gov
inferred← citeshttps://doi.org/10.1007/s13671-023-00395-8openalex-snapshot
Clinical Features and Management of Dermatologic Immune-Related Adverse Events for the Inpatient Dermatologist
inferred← citeshttps://doi.org/10.1007/s15002-021-3328-xopenalex-snapshot
Diagnostik und Management rheumatischer "immune-related adverse events"
inferred← citeshttps://doi.org/10.1007/s15012-025-8696-5openalex-snapshot
Immuncheckpointinhibitoren bei Autoimmunerkrankungen
inferred← citeshttps://doi.org/10.1007/s15015-024-3900-8openalex-snapshot
Immuncheckpointinhibitoren bei Autoimmunerkrankungen
inferred← citeshttps://doi.org/10.1007/s40135-023-00312-zopenalex-snapshot
Update on Immune Checkpoint Inhibitor-Associated Uveitis
inferred← citeshttps://doi.org/10.1007/s40257-024-00866-zopenalex-snapshot
The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases
inferred← citeshttps://doi.org/10.1007/s40265-018-0970-yopenalex-snapshot
Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma
inferred← citeshttps://doi.org/10.1007/s40618-020-01306-5openalex-snapshot
The role of immune checkpoint inhibitor therapy in advanced adrenocortical carcinoma revisited: review of literature
inferred← citeshttps://doi.org/10.1007/s40674-019-00131-zopenalex-snapshot
Immune Checkpoint Inhibitor Associated Rheumatic Adverse Events: a Review of Their Presentations and Treatments
inferred← citeshttps://doi.org/10.1007/s44178-023-00040-1openalex-snapshot
CACA guidelines for holistic integrative management of nasopharyngeal carcinoma
inferred← citeshttps://doi.org/10.1016/b978-0-12-821976-8.00010-4openalex-snapshot
Neurological complications of steroids and of supportive care
inferred← citeshttps://doi.org/10.1016/b978-0-323-69573-2.00017-6openalex-snapshot
First-line therapy
inferred← citeshttps://doi.org/10.1016/b978-0-443-33565-5.00009-8openalex-snapshot
Challenges in traditional TNBC therapies
inferred← citeshttps://doi.org/10.1016/j.abd.2020.01.001openalex-snapshot
Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel
inferred← citeshttps://doi.org/10.1016/j.abdp.2020.01.002openalex-snapshot
10.1016/j.abdp.2020.01.002
inferred← citeshttps://doi.org/10.1016/j.addr.2021.114035openalex-snapshot
Smart biomaterials to enhance the efficiency of immunotherapy in glioblastoma: State of the art and future perspectives
inferred← citeshttps://doi.org/10.1016/j.addr.2024.115332openalex-snapshot
Novel strategies for modulating the gut microbiome for cancer therapy
inferred← citeshttps://doi.org/10.1016/j.adro.2020.10.019openalex-snapshot
Usefulness of Simple Original Interstitial Lung Abnormality Scores for Predicting Radiation Pneumonitis Requiring Steroidal Treatment After Definitive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1016/j.ajoms.2024.02.001openalex-snapshot
A case of eosinophilic gastroenteritis developed during administration of nivolumab for a patient with platinum-resistant head and neck cancer
inferred← citeshttps://doi.org/10.1016/j.ajur.2022.02.016openalex-snapshot
A durable complete response resulting from treatment with nivolumab plus ipilimumab for metastatic collecting duct carcinoma of the kidney
inferred← citeshttps://doi.org/10.1016/j.anl.2021.02.002openalex-snapshot
Nivolumab for recurrent/metastatic hypopharyngeal squamous cell carcinoma in a liver transplant recipient
inferred← citeshttps://doi.org/10.1016/j.annonc.2019.12.002openalex-snapshot
Deep androgen receptor suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure
inferred← citeshttps://doi.org/10.1016/j.annonc.2020.03.285openalex-snapshot
Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy
inferred← citeshttps://doi.org/10.1016/j.annonc.2020.11.003openalex-snapshot
Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up
inferred← citeshttps://doi.org/10.1016/j.arcmed.2021.09.004openalex-snapshot
Rheumatological Adverse Events of Cancer Therapy with Immune Checkpoint Inhibitors
inferred← citeshttps://doi.org/10.1016/j.ard.2026.02.017openalex-snapshot
Oral glucocorticoid treatment for checkpoint inhibitor-associated inflammatory arthritis does not affect cancer progression-free survival: a RADIOS Registry study
inferred← citeshttps://doi.org/10.1016/j.autrev.2020.102687openalex-snapshot
Immune checkpoint inhibitors therapies in patients with cancer and preexisting autoimmune diseases: A meta-analysis of observational studies
inferred← citeshttps://doi.org/10.1016/j.bbcan.2023.189008openalex-snapshot
Reflecting on the cardiac toxicity in non-small cell lung cancer in the era of immune checkpoint inhibitors therapy combined with thoracic radiotherapy
inferred← citeshttps://doi.org/10.1016/j.beha.2025.101625openalex-snapshot
Precision immunomodulation: Understanding and harnessing cytokine pathways to treat and prevent immune-related adverse events (irAEs)
inferred← citeshttps://doi.org/10.1016/j.berh.2019.101472openalex-snapshot
The relationships between cancer and autoimmune rheumatic diseases
inferred← citeshttps://doi.org/10.1016/j.berh.2020.101511openalex-snapshot
Immunologic adverse events from immune checkpoint therapy
inferred← citeshttps://doi.org/10.1016/j.berh.2026.102147openalex-snapshot
The management of rheumatic immune related adverse events
inferred← citeshttps://doi.org/10.1016/j.biomaterials.2020.120407openalex-snapshot
Improving safety of cancer immunotherapy via delivery technology
inferred← citeshttps://doi.org/10.1016/j.biomaterials.2025.123419openalex-snapshot
Advanced biomaterials and delivery modalities to alleviate cancer therapy-induced inflammation
inferred← citeshttps://doi.org/10.1016/j.biopha.2022.112687openalex-snapshot
Comparison of immune checkpoint inhibitor-induced arthritis and reactive arthritis to inform therapeutic strategy
inferred← citeshttps://doi.org/10.1016/j.bulcan.2021.01.015openalex-snapshot
Impact de l’utilisation de la corticothérapie systémique sur l’efficacité des inhibiteurs de points de contrôle immunitaire
inferred← citeshttps://doi.org/10.1016/j.bulcan.2021.01.016openalex-snapshot
Effets secondaires rhumatologiques immuno-induits par les inhibiteurs de points de contrôle de la réponse immunitaire
inferred← citeshttps://doi.org/10.1016/j.canlet.2024.217241openalex-snapshot
Immune checkpoint inhibitors rechallenge in non-small cell lung cancer: Current evidence and future directions
inferred← citeshttps://doi.org/10.1016/j.canlet.2026.218840openalex-snapshot
Epithelial HSD11β2 as an immunometabolic checkpoint in head and neck cancer: Restoring local steroid inactivation reinvigorates T cell immunity
inferred← citeshttps://doi.org/10.1016/j.canlet.2026.218860openalex-snapshot
Radiation-induced cell-death states in cancer: Toward biomarker-guided radioimmunotherapy
inferred← citeshttps://doi.org/10.1016/j.ccell.2019.10.013openalex-snapshot
Stressing Out about Cancer Immunotherapy
inferred← citeshttps://doi.org/10.1016/j.ccell.2021.09.010openalex-snapshot
Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer
inferred← citeshttps://doi.org/10.1016/j.ccell.2025.01.004openalex-snapshot
Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity
inferred← citeshttps://doi.org/10.1016/j.ccm.2020.02.012openalex-snapshot
Pulmonary Complications of Immunotherapy
inferred← citeshttps://doi.org/10.1016/j.cell.2020.06.001openalex-snapshot
Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy
inferred← citeshttps://doi.org/10.1016/j.cell.2021.02.011openalex-snapshot
Understanding and treating the inflammatory adverse events of cancer immunotherapy
inferred← citeshttps://doi.org/10.1016/j.cell.2021.09.020openalex-snapshot
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
inferred← citeshttps://doi.org/10.1016/j.cellsig.2019.109391openalex-snapshot
MicroRNA-6077 enhances the sensitivity of patients-derived lung adenocarcinoma cells to anlotinib by repressing the activation of glucose transporter 1 pathway
inferred← citeshttps://doi.org/10.1016/j.clbc.2020.11.016openalex-snapshot
Use of Immune Checkpoint Inhibitors in Early Triple-Negative Breast Cancer: Beyond the Early Conflicting Results
showing the first 200 of 1059 · page through all 1059
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.